1 BTC
=
- USD
Iovance Biotherapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Market Statistics
Trading Metrics
How to Buy IOVA
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy IOVA
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesIovance Biotherapeutics approved the grant of inducement stock options covering 93,340 shares to thirteen new non-executive employees on May 21, 2026, with an exercise price of $3.70 per share and a three-year vesting schedule.
Iovance Biotherapeutics (IOVA) has surged 34% in 2026 but lost 90% over five years. Wall Street analysts project a 165% upside to $9, driven by strong revenue growth (61% YoY) from its melanoma drug Amtagvi and potential expansion into lung cancer. However, the analyst remains skeptical, citing manufacturing complexity, high costs, and regulatory hurdles that could prevent the stock from reaching the $9 target within 12 months.
Iovance Biotherapeutics' oncology drug Amtagvi is generating strong sales growth and expanding globally, with potential to exceed $1 billion annually by 2030. However, the company faces significant risks including high manufacturing costs, complex cell therapy administration, and regulatory uncertainties. The stock is recommended as a small initial position due to its high-risk, high-reward profile.
The Proleukin market is projected to grow from $1.24 million in 2025 to $1.68 million by 2030, with a CAGR of 6.1%. Growth drivers include rising cancer prevalence, increased cystic fibrosis diagnoses, enhanced R&D investments, and the drug's approval for respiratory and oncology applications. Iovance Biotherapeutics acquired Proleukin in May 2023, strengthening its immunotherapy platform. North America currently leads the market, while Asia-Pacific is expected to be the fastest-growing region.
The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaà Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.
